Arvinas
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Connecticut, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
5 Science Park 395, New Haven, Connectic...Phone Number
(203) 535-1456Website
www.arvinas.comRevenue
$89.4 MillionStock Symbol
ARVNIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Arvinas
Founded in 2013, Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company's headquarters in New Haven, Connecticut.Explore more
Arvinas Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arvinas your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Arvinas recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Arvinas
Click to see if Arvinas had a recent Job posting/layoffs
Arvinas, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Arvinas has new funding data
Check if Arvinas has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Arvinas launches new products
Check out if Arvinas is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Arvinas
Find more new buyers
Compare Similar Companies to Arvinas
Compare insights from companies similar to Arvinas, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Arvinas is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Arvinas is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Arvinas.
Arvinas financials insights
Gather financial insights about Arvinas, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Corporate Investment
$3.3M
Series A
$15M
2015
Series B
$41.6M
2018
Series C
$55M
Stock Offering
$120M
Arvinas Tech Stack
A closer look at the technologies used by Arvinas
See more technologies
Most Recent Scoops
Open Position
Project
plans to share additional biomarker data from the ARV-102 Phase I trial later this year and initiate both a Phase I-B and a Phase II trial in patients with progressive supranuclear palsy (PSP) this year.
Medical Research, Clinical Operations
Partnership
Partnership, Product Management, Business Development, Intellectual Property, Legal Affairs, Pharmaceuticals, Manufacturing Operations
Project
Arvinas has initiated a Phase I study for ARV-027 in healthy volunteers, with patients with spinal and bulbar muscular atrophy (SBMA) to be added at the end of the study, including muscle biopsies to demonstrate dose-dependent degradation of the androgen receptor.
Medical Research, Clinical Operations
Project
Medical Research
Arvinas News & Media
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
NEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has recently joined the LRRK2 Investigative Therapeutics Exchange (LITE) program and the Parkinson’s Precision Medicine Initiative (PPMI), both supported by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).Arvinas to Present at Jefferies Global Healthcare Conference
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.Arvinas Employees Give Back During Company-wide Impact Day
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Connecticut, in the Greater Boston area, and around the country, took part in the Company’s fourth Arvinas Impact Day this past Friday. This company-wide day of service brings employees together to give back to their communities through volunteer activities thatArvinas Q1 Earnings Call Highlights
Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation. President and Chief Executive Officer Randy Teel said the app
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Arvinas
Sign Up For FreeTo access detailed company insights
Founded in 2013, Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company's headquarters in New Haven, Connecticut.... Read More
